Drug Profile
Research programme: melanoma vaccine - Aastrom Biosciences
Latest Information Update: 18 May 2006
Price :
$50
*
At a glance
- Originator Aastrom Biosciences
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 18 May 2006 Discontinued - Preclinical for Malignant melanoma in USA (unspecified route)
- 14 May 2004 Preclinical trials in Malignant melanoma in USA (unspecified route)